These studies warrant consideration of BMI in therapeutic decisions, and including higher doses of tamoxifen or aromatase inhibitors as well as improved combination regimens that can effectively treat obese ER+PR+ breast cancer patients. Here, CYP19A1 is linked to breast cancer.